| Literature DB >> 35877715 |
Eleonora Montuori1,2, Donatella de Pascale2, Chiara Lauritano2.
Abstract
Marine organisms have been shown to be a valuable source for biologically active compounds for the prevention and treatment of cancer, inflammation, immune system diseases, and other pathologies. The advantage of studying organisms collected in the marine environment lies in their great biodiversity and in the variety of chemical structures of marine natural products. Various studies have focused on marine organism compounds with potential pharmaceutical applications, for instance, as immunomodulators, to treat cancer and immune-mediated diseases. Modulation of the immune system is defined as any change in the immune response that can result in the induction, expression, amplification, or inhibition of any phase of the immune response. Studies very often focus on the effects of marine-derived compounds on macrophages, as well as lymphocytes, by analyzing the release of mediators (cytokines) by using the immunological assay enzyme-linked immunosorbent assay (ELISA), Western blot, immunofluorescence, and real-time PCR. The main sources are fungi, bacteria, microalgae, macroalgae, sponges, mollusks, corals, and fishes. This review is focused on the marine-derived molecules discovered in the last three years as potential immunomodulatory drugs.Entities:
Keywords: cancer; immunomodulatory activity; inflammation; marine drugs; marine organisms
Mesh:
Substances:
Year: 2022 PMID: 35877715 PMCID: PMC9324980 DOI: 10.3390/md20070422
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 6.085
Figure 1Immunomodulatory effects of marine-derived compounds. TNFα stands for tumor necrosis factor alpha, IL-1 for interleukin-1, IL-6 for interleukin-6, and NO for nitric oxide.
Figure 2The figure shows the compounds which target the immune system approved by the Food and Drug Administration (FDA) for marketing (https://www.midwestern.edu/departments/marinepharmacology/clinical-pipeline; accessed on 5 May 2022).
Compounds/extracts from marine microorganisms with immunomodulatory activity. YCP stands for α-D-glucan, IL-6 for interleukin 6, IL-1 β for interleukin 1β, TNF-α for tumor necrosis factor alpha, DSS for dextran sodium sulfate, SOD for superoxide dismutase, and CAT for catalase.
| Compound/Extract | Activity (Cells) | Organism | Mechanism of Action | Active Concentration | Reference |
|---|---|---|---|---|---|
| α- | Immunomodulatory functions by regulating T lymphocytes and dendritic cells in vitro. | Marine fungus | After 7 days, there was relief in the clinical symptoms of mice with colitis, restoration of intestinal immune homeostasis, and remission of mucosal damage. | In vivo: 40 mg/kg | [ |
| Irish deep-sea organism extracts | Induce human mesenchymal stem cell (hMSC) differentiation. | Filamentous fungi | Reduced the production of pro-inflammatory cytokines, such as TNFα and IL-1β. | In vitro: 125 µg/mL | [ |
| β-carotene | Anti-inflammatory | Microalgae | Docked pro-inflammatory proteins IL-6 | In silico study | [ |
| Phycocyanobilin | Anti-inflammatory | Microalgae | Docked pro-inflammatory protein NF-κB inducing kinase (NIK) with binding energy −9.9 Kcal/mol. | In silico study | [ |
| 9-cis-β-carotene | Anti-inflammatory | Microalgae | Docked pro-inflammatory protein TNF-α with binding energy −7.9 Kcal/mol. | In silico study | [ |
| Exopolysaccharides (EPS) | Immunostimulatory | Microalga | Increase in total hemocytes (THC) value, | Treatment with increasing concentration of EPS | [ |
| β-glucans | Immunostimulatory, | Microalga | Elicited an inflammatory response with the downregulation of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α; activated the host’s innate immune cells; | 0.6 g β-glucans per kg of feed | [ |
Compounds/extracts from marine macroorganisms with immunomodulatory activity. The IL-1β stands for interleukin 1 β, IL-6 for interleukin 6, IL-10 for interleukin 10, LPS for lipopolysaccharide, TNF-α for tumor necrosis factor alpha, INF-γ for interferon gamma, MODCs for monocyte-derived dendritic cells, PBDCs for peripheral blood dendritic cells, NO for nitric oxide, ERO for endoplasmic reticulum oxidoreductin, and TGF-β for transforming growth factor beta.
| Compound/Extract | Activity (Cells) | Organism | Mechanism of Action | Active Concentration | Reference |
|---|---|---|---|---|---|
| Ulvan | Immunomodulatory activity | Alga: | Increases in IL-1β, IL-6, and IL-10; improves LPS-induced inflammation; and a decreases prostaglandin E2. | 100 µg/mL in vitro | [ |
| Fucoidan | Immunostimulatory activity | Algae: | Increases the production of IL-6, IL-12, and TNF-α in MODCs and PBDCs; induces INF-γ production. | 100 µg/mL in vitro | [ |
| Sulphated polysaccharides: sulfated galactans and pyruvates (named SP1 and SP2) | Immunostimulatory activity | Alga: | Increased production of NO, ERO, and the cytokines IL-6 and TNF-α in murine macrophages RAW 264.7. | 100 µg/mL in vitro | [ |
| Sulphated oligosaccharide(GLSO) | Immunomodulatory activity | Alga: | Inhibits the production of INF-γ by T cells in ovalbumin (OVA) immunized mice and in vitro activation system of OVA-specific CD4+ T cells; | [ | |
| Crude extract | Immunomodulatory activity | Sponge: | Decrease of immune cells (WBC, lymphocytes, platelets, BMC, and splenocytes) and of the splenocytic index; | In vivo 15 mg/kg; 10 mg/kg; 5 mg/kg. | [ |
| ThisAgeliferins derivates | Immunomodulatory activity | Sponge: | Inhibition of Cbl-b ubiquitin ligase activity (IC50 values ranging from 18 to 35 µM); | 10–50 µM | [ |
| ASPG-2 polysaccharide | Immunomodulatory activity | Mollusk: | promotes NO secretion; | In vitro: 250 μg/mL and 500 μg/mL for 24 h | [ |
| Polysaccharides | Immunomodulatory activity | Mollusk: | Promotes the abundance of some probiotics in the colon. | In vitro: 300 μg/mL and 600 μg/mL | [ |
| Protein HPCG2 | Immunomodulatory activity | Mollusk: | Promotes the phosphorylation of Akt, ERK, and JNK. | In vitro: 250 μg/mL and 500 μg/mL | [ |
| Polysaccharide PPA | Immunomodulatory | Coral: | Induces pro-inflammatory mediator expression in macrophages via ROS-, MAPK-, PKC-α/δ-, and NF-κB-dependent pathways. | In vitro: 10 μg/mL | [ |
| BpNK-Lysine | Immunomodulatory activity | Fish: | In vivo, decreased the tissue bacterial burden of mudskipper infected by | In vivo: injection of 1.0 µg/g | [ |